Home
From Wikipedia, the free encyclopedia
v
t
e
Drug design
Steps in design
Drug discovery
Hit to lead
Drug development
Preclinical
Clinical
Phases
Case studies of discovery
and development of drug classes
5α-Reductase inhibitors
ACE inhibitors
Angiotensin receptor blockers
Antiandrogens
Beta-blockers
Beta
2
agonists
Cephalosporins
c-Met inhibitors
Cyclooxygenase 2 inhibitors
Dipeptidyl peptidase-4 inhibitors
Direct thrombin inhibitors
Direct Xa inhibitors
Dual serotonin and norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors
Gliflozins
HIV-protease inhibitors
Integrase inhibitors
Lipase inhibitors
Memantine and related drugs
mTOR inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse-transcriptase inhibitors
NS5A inhibitors
Nucleoside and nucleotide reverse-transcriptase inhibitors
PDE5 inhibitors
Proton pump inhibitors
Statins
Thalidomide and its analogs
Triptans
TRPV1 antagonists
Tubulin inhibitors
Bcr-Abl tyrosine-kinase inhibitors
Cannabinoid receptor antagonists
CCR5 receptor antagonists
Neurokinin 1 receptor antagonists
5-HT
3
antagonists
Melatonin receptor agonists
Renin inhibitors
Template documentation
This template's
documentation
is
missing, inadequate, or does not accurately describe its functionality and/or the
parameters
in its code.
Please help
to expand and improve it
.
Editors can experiment in this template's sandbox
(
create
|
mirror
)
and testcases
(
create
)
pages.
Subpages of this template
.
Category
:
Drug navigational boxes
Hidden category:
Templates with missing or incorrect documentation